The market has been down on Bright Minds Biosciences Inc (DRUG) stock recently. DRUG gets a Bearish score fromInvestorsObserverStock Sentiment Indicator.
What is Stock Sentiment?
In investing, sentiment generally means whether or not a given security is in favor with investors. It is typically a pretty short-term metric that relies entirely on technical analysis. That means it doesn’t incorporate anything to do with the health or profitability of the underlying company. Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish.InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion. For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.
What's Happening With DRUG Stock Today?
Bright Minds Biosciences Inc (DRUG) stock is trading at $1.72 as of 10:14 AM on Monday, Aug 22, a rise of $0.47, or 37.54% from the previous closing price of $1.25. The stock has traded between $1.16 and $1.88 so far today. Volume today is low. So far 425,159 shares have traded compared to average volume of 4,337,795 shares.To screen for more stocks like Bright Minds Biosciences Inc click here.More About Bright Minds Biosciences IncBright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.$Bright Minds Biosciences Inc(DRUG)$
Comments